{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T09:59:04Z","timestamp":1781344744218,"version":"3.54.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["112-2320-B-040-"],"award-info":[{"award-number":["112-2320-B-040-"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007647","name":"College of Medicine, National Taiwan University","doi-asserted-by":"publisher","award":["NTUCCS-112-07"],"award-info":[{"award-number":["NTUCCS-112-07"]}],"id":[{"id":"10.13039\/501100007647","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00428-025-04364-3","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T02:59:59Z","timestamp":1764817199000},"page":"1217-1225","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Acquired MYC rearrangement potentially associated with ibrutinib resistance in mantle cell lymphoma"],"prefix":"10.1007","volume":"488","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1438-9187","authenticated-orcid":false,"given":"Chang-Tsu","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Yu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chieh-Lung","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bor-Sheng","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6840-2976","authenticated-orcid":false,"given":"Wei-Li","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"4364_CR1","unstructured":"Sarah E. Coupland, German Ott, William Arthur Sewell, et al. Mantle cell lymphoma. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer."},{"issue":"9873","key":"4364_CR2","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G et al (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381(9873):1203\u20131210. https:\/\/doi.org\/10.1016\/S0140-6736(12)61763-2","journal-title":"Lancet"},{"issue":"19","key":"4364_CR3","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, van der Jagt R, Kahl BS et al (2014) Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 123(19):2944\u20132952. https:\/\/doi.org\/10.1182\/blood-2013-11-531327","journal-title":"Blood"},{"issue":"6","key":"4364_CR4","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P et al (2013) Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369(6):507\u2013516. https:\/\/doi.org\/10.1056\/NEJMoa1306220","journal-title":"N Engl J Med"},{"issue":"10020","key":"4364_CR5","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","volume":"387","author":"M Dreyling","year":"2016","unstructured":"Dreyling M, Jurczak W, Jerkeman M et al (2016) Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet 387(10020):770\u2013778. https:\/\/doi.org\/10.1016\/S0140-6736(15)00667-4","journal-title":"Lancet"},{"issue":"26","key":"4364_CR6","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","volume":"386","author":"ML Wang","year":"2022","unstructured":"Wang ML, Jurczak W, Jerkeman M et al (2022) Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N Engl J Med 386(26):2482\u20132494. https:\/\/doi.org\/10.1056\/NEJMoa2201817","journal-title":"N Engl J Med"},{"issue":"9","key":"4364_CR7","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","volume":"4","author":"D Chiron","year":"2014","unstructured":"Chiron D, Di Liberto M, Martin P et al (2014) Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discov 4(9):1022\u20131035. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-0098","journal-title":"Cancer Discov"},{"issue":"491","key":"4364_CR8","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau1167","volume":"11","author":"L Zhang","year":"2019","unstructured":"Zhang L, Yao Y, Zhang S et al (2019) Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Sci Transl Med 11(491):eaau1167. https:\/\/doi.org\/10.1126\/scitranslmed.aau1167","journal-title":"Sci Transl Med"},{"issue":"1","key":"4364_CR9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","volume":"25","author":"R Agarwal","year":"2019","unstructured":"Agarwal R, Chan YC, Tam CS et al (2019) Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. Nat Med 25(1):119\u2013129. https:\/\/doi.org\/10.1038\/s41591-018-0243-z","journal-title":"Nat Med"},{"key":"4364_CR10","doi-asserted-by":"publisher","first-page":"14920","DOI":"10.1038\/ncomms14920","volume":"8","author":"X Zhao","year":"2017","unstructured":"Zhao X, Lwin T, Silva A et al (2017) Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. Nat Commun 8:14920. https:\/\/doi.org\/10.1038\/ncomms14920","journal-title":"Nat Commun"},{"issue":"20","key":"4364_CR11","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1182\/blood.2024023818","volume":"143","author":"CT Yuan","year":"2024","unstructured":"Yuan CT, Ma WL (2024) Transformed mantle cell lymphoma with additional triple-hit genotypes can be resistant to a Bruton tyrosine kinase inhibitor. Blood 143(20):2106. https:\/\/doi.org\/10.1182\/blood.2024023818","journal-title":"Blood"},{"issue":"2","key":"4364_CR12","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/PAS.0000000000000758","volume":"41","author":"Z Hu","year":"2017","unstructured":"Hu Z, Medeiros LJ, Chen Z et al (2017) Mantle cell lymphoma with MYC rearrangement: a report of 17 patients. Am J Surg Pathol 41(2):216\u2013224. https:\/\/doi.org\/10.1097\/PAS.0000000000000758","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"4364_CR13","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.3324\/haematol.2023.283352","volume":"109","author":"JM Rodrigues","year":"2024","unstructured":"Rodrigues JM, Hollander P, Schmidt L et al (2024) MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and TP53\/p53 - a Nordic Lymphoma Group study. Haematologica 109(4):1171\u20131183. https:\/\/doi.org\/10.3324\/haematol.2023.283352","journal-title":"Haematologica"},{"issue":"5","key":"4364_CR14","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.3324\/haematol.2019.243071","volume":"106","author":"L Wang","year":"2021","unstructured":"Wang L, Tang G, Medeiros LJ et al (2021) MYC rearrangement but not extra MYC copies is an independent prognostic factor in patients with mantle cell lymphoma. Haematologica 106(5):1381\u20131389. https:\/\/doi.org\/10.3324\/haematol.2019.243071","journal-title":"Haematologica"},{"issue":"18","key":"4364_CR15","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1182\/blood-2017-02-770503","volume":"129","author":"J Xu","year":"2017","unstructured":"Xu J, Li S (2017) Triple-hit blastoid mantle cell lymphoma presenting like acute leukemia. Blood 129(18):2593. https:\/\/doi.org\/10.1182\/blood-2017-02-770503","journal-title":"Blood"},{"issue":"4","key":"4364_CR16","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/bjh.17729","volume":"195","author":"W Liu","year":"2021","unstructured":"Liu W, Chen X, Fan J et al (2021) Quadruple-hit pleomorphic mantle cell lymphoma with MYC, BCL2, BCL6, and CCND1 gene rearrangements. Br J Haematol 195(4):634\u2013637. https:\/\/doi.org\/10.1111\/bjh.17729","journal-title":"Br J Haematol"},{"issue":"6","key":"4364_CR17","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1111\/his.13161","volume":"70","author":"WY Chuang","year":"2017","unstructured":"Chuang WY, Chang H, Chang GJ et al (2017) Pleomorphic mantle cell lymphoma morphologically mimicking diffuse large B cell lymphoma: common cyclin D1 negativity and a simple immunohistochemical algorithm to avoid the diagnostic pitfall. Histopathology 70(6):986\u2013999. https:\/\/doi.org\/10.1111\/his.13161","journal-title":"Histopathology"},{"issue":"27","key":"4364_CR18","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059\u20133068. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800","journal-title":"J Clin Oncol"},{"issue":"4","key":"4364_CR19","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/his.14726","volume":"81","author":"MJ Fitzpatrick","year":"2022","unstructured":"Fitzpatrick MJ, Boiocchi L, Fathi AT, Brunner AM, Hasserjian RP, Nardi V (2022) Correlation of p53 immunohistochemistry with TP53 mutational status and overall survival in newly diagnosed acute myeloid leukaemia. Histopathology 81(4):496\u2013510. https:\/\/doi.org\/10.1111\/his.14726","journal-title":"Histopathology"},{"key":"4364_CR20","unstructured":"R Core Team. R: A language and environment for statistical computing. Published online 2022. https:\/\/www.R-project.org\/.\u00a0Accessed Dec 31 2023"},{"key":"4364_CR21","unstructured":"RStudio Team. RStudio: integrated development environment for R. Published online 2022. http:\/\/www.rstudio.com\/.\u00a0Accessed Dec 31 2023"},{"issue":"Supplement_1","key":"4364_CR22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127863","volume":"134","author":"M Dreyling","year":"2019","unstructured":"Dreyling M, Ladetto M, Doorduijn JK et al (2019) Triangle: autologous transplantation after a rituximab\/ibrutinib\/ara-c containing induction in generalized mantle cell lymphoma - a randomized European MCL network trial. Blood 134(Supplement_1):2816. https:\/\/doi.org\/10.1182\/blood-2019-127863","journal-title":"Blood"},{"issue":"16","key":"4364_CR23","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1182\/bloodadvances.2018016048","volume":"2","author":"J Lee","year":"2018","unstructured":"Lee J, Zhang LL, Wu W et al (2018) Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma. Blood Adv 2(16):2039\u20132051. https:\/\/doi.org\/10.1182\/bloodadvances.2018016048","journal-title":"Blood Adv"},{"issue":"6","key":"4364_CR24","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.3324\/haematol.2022.281538","volume":"108","author":"L Li","year":"2022","unstructured":"Li L, Nie L, Jordan A et al (2022) Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma. Haematologica 108(6):1616\u20131627. https:\/\/doi.org\/10.3324\/haematol.2022.281538","journal-title":"Haematologica"},{"issue":"3","key":"4364_CR25","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1182\/blood-2016-05-718775","volume":"129","author":"B Dai","year":"2017","unstructured":"Dai B, Grau M, Juilland M et al (2017) B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma. Blood 129(3):333\u2013346. https:\/\/doi.org\/10.1182\/blood-2016-05-718775","journal-title":"Blood"},{"issue":"9","key":"4364_CR26","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1182\/blood-2011-11-391474","volume":"119","author":"R Kridel","year":"2012","unstructured":"Kridel R, Meissner B, Rogic S et al (2012) Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood 119(9):1963\u20131971. https:\/\/doi.org\/10.1182\/blood-2011-11-391474","journal-title":"Blood"},{"issue":"3","key":"4364_CR27","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.celrep.2017.09.066","volume":"21","author":"RJH Ryan","year":"2017","unstructured":"Ryan RJH, Petrovic J, Rausch DM et al (2017) A B cell regulome links notch to downstream oncogenic pathways in small B cell lymphomas. Cell Rep 21(3):784\u2013797. https:\/\/doi.org\/10.1016\/j.celrep.2017.09.066","journal-title":"Cell Rep"},{"issue":"1","key":"4364_CR28","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s12308-014-0229-9","volume":"8","author":"ME Kallen","year":"2015","unstructured":"Kallen ME, Rao NP, Kulkarni SK et al (2015) B-lymphoblastic transformation of mantle cell lymphoma\/leukemia with \u201cdouble hit\u201d changes. J Hematopathol 8(1):31\u201336. https:\/\/doi.org\/10.1007\/s12308-014-0229-9","journal-title":"J Hematopathol"},{"issue":"1","key":"4364_CR29","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00428-021-03022-8","volume":"479","author":"SM Aukema","year":"2021","unstructured":"Aukema SM, Croci GA, Bens S et al (2021) Mantle cell lymphomas with concomitant MYC and CCND1 breakpoints are recurrently TdT positive and frequently show high-grade pathological and genetic features. Virchows Arch 479(1):133\u2013145. https:\/\/doi.org\/10.1007\/s00428-021-03022-8","journal-title":"Virchows Arch"},{"issue":"20","key":"4364_CR30","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1182\/bloodadvances.2018023572","volume":"2","author":"LC Chong","year":"2018","unstructured":"Chong LC, Ben-Neriah S, Slack GW et al (2018) High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology. Blood Adv 2(20):2755\u20132765. https:\/\/doi.org\/10.1182\/bloodadvances.2018023572","journal-title":"Blood Adv"},{"issue":"2","key":"4364_CR31","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jmoldx.2017.11.010","volume":"20","author":"SS Hung","year":"2018","unstructured":"Hung SS, Meissner B, Chavez EA et al (2018) Assessment of capture and amplicon-based approaches for the development of a targeted next-generation sequencing pipeline to personalize lymphoma management. J Mol Diagn 20(2):203\u2013214. https:\/\/doi.org\/10.1016\/j.jmoldx.2017.11.010","journal-title":"J Mol Diagn"},{"issue":"1","key":"4364_CR32","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1038\/s41467-021-23695-8","volume":"12","author":"A Allahyar","year":"2021","unstructured":"Allahyar A, Pieterse M, Swennenhuis J et al (2021) Robust detection of translocations in lymphoma FFPE samples using targeted locus capture-based sequencing. Nat Commun 12(1):3361. https:\/\/doi.org\/10.1038\/s41467-021-23695-8","journal-title":"Nat Commun"},{"issue":"11","key":"4364_CR33","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1200\/JCO.21.02321","volume":"40","author":"E Gin\u00e9","year":"2022","unstructured":"Gin\u00e9 E, de la Cruz F, Jim\u00e9nez Ubieto A et al (2022) Ibrutinib in combination with rituximab for indolent clinical forms of mantle cell lymphoma (IMCL-2015): a multicenter, open-label, single-arm, phase II trial. J Clin Oncol 40(11):1196\u20131205. https:\/\/doi.org\/10.1200\/JCO.21.02321","journal-title":"J Clin Oncol"},{"issue":"5","key":"4364_CR34","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000712","volume":"6","author":"M Dreyling","year":"2022","unstructured":"Dreyling M, Goy A, Hess G et al (2022) Long-term outcomes with ibrutinib treatment for patients with relapsed\/refractory mantle cell lymphoma: a pooled analysis of 3 clinical trials with nearly 10 years of follow-up. Hemasphere 6(5):e712. https:\/\/doi.org\/10.1097\/HS9.0000000000000712","journal-title":"Hemasphere"},{"issue":"3","key":"4364_CR35","doi-asserted-by":"publisher","first-page":"e109","DOI":"10.1016\/S2352-3026(18)30018-8","volume":"5","author":"M Jerkeman","year":"2018","unstructured":"Jerkeman M, Eskelund CW, Hutchings M et al (2018) Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. Lancet Haematol 5(3):e109\u2013e116. https:\/\/doi.org\/10.1016\/S2352-3026(18)30018-8","journal-title":"Lancet Haematol"},{"issue":"4","key":"4364_CR36","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/cjp2.53","volume":"2","author":"M K\u00f6bel","year":"2016","unstructured":"K\u00f6bel M, Piskorz AM, Lee S et al (2016) Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. J Pathol Clin Res 2(4):247\u2013258. https:\/\/doi.org\/10.1002\/cjp2.53","journal-title":"J Pathol Clin Res"},{"key":"4364_CR37","doi-asserted-by":"crossref","unstructured":"Hernandez L, Fest T, Cazorla M et al (1996) P53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood 87(8):3351\u20133359","DOI":"10.1182\/blood.V87.8.3351.bloodjournal8783351"},{"key":"4364_CR38","doi-asserted-by":"publisher","unstructured":"Aukema SM, Hoster E, Rosenwald A et al (2018) Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network. Blood 131(4):417\u2013420. https:\/\/doi.org\/10.1182\/blood-2017-07-797019","DOI":"10.1182\/blood-2017-07-797019"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-025-04364-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-025-04364-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-025-04364-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T09:54:25Z","timestamp":1781344465000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-025-04364-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4364"],"URL":"https:\/\/doi.org\/10.1007\/s00428-025-04364-3","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]},"assertion":[{"value":"11 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Adherence to ethical standards stipulated in the Declaration of Helsinki was ensured throughout the conduct of this study, with formal approval obtained from the National Taiwan University Hospital Research Ethics Committee (no. 202405058RINA).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The Research Ethics Committee agreed to waive the consents in this retrospective observational study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}